Bringing back what’s been lost

We’re rewilding what modern life has stripped away. Our clinically informed microbiome therapeutics are built both for today and for the next era of medicine.

Invest in the future of medicine

BiomeBank is redefining healthcare by rewilding the gut ecosystem. We invite you to unlock the full potential of microbiome medicine with us.

Advancing microbiome therapeutics

Modern life has stripped away our native gut microbes and chronic disease has surged.

The future of human health depends on reversing this decline, with a new frontier in medicine.

BiomeBank is pioneering a new class of microbiome therapeutics designed to restore this lost ecological complexity and reshape the future of medicine.

We’re developing next-generation, co-cultured microbial products that move beyond the limits of single-strain approaches — therapies designed with the diversity of nature and the precision and scalability to meet global health challenges.

You can’t rebuild a rainforest with a single tree

Like many thriving ecosystems in nature, diversity is the key ingredient for a healthy gut microbiome. Our technology rewilds the gut ecosystem to unlock whole-system health.

Learn more

Next-gen therapeutics

Microbial ecosystems, designed for whole-system impact

Powered by our proprietary CONSORTIOME® platform and informed by one of the world’s largest gut microbiome collections, we’re developing living therapies that reflect the complexity of the human gut — with precision, consistency and scalability.

We are advancing our pipeline with next-generation co-cultured therapeutics, beginning with our lead candidate for ulcerative colitis, while exploring applications across immunity, metabolism, neurology and oncology – unlocking the potential to transform health on a global scale.

Next-gen therapeutics

Invest / Partner with us

Invest in the future of medicine

The microbiome field represents a multi-billion-dollar market poised for rapid growth. Investors have the chance to be part of a sector that will reshape healthcare and unlock entirely new opportunities for value creation.

BiomeBank has proven experience navigating regulation, bringing therapies to market, and turning breakthrough science into real-world impact. With a platform built for scale and a clear path ahead, at BiomeBank, saving lives and generating returns go hand in hand.

Invest in our growth

Available therapeutics

Life-saving microbiome therapies are here

In 2022, we launched BIOMICTRA®, the world’s first regulated donor-derived therapy, now widely used to treat recurrent Clostridioides difficile infection.

BIOMICTRA® is available to licensed medical practitioners in Australia. With BIOMICTRA®, we’re delivering life-saving treatment today and building the foundation for tomorrow’s breakthroughs, including an even more accessible FMT capsule therapy, planned for launch in late 2026.

Order BIOMICTRA®
Our products

Team

Our multidisciplinary team stands at the forefront of microbiome research

Get to know us
See our facilities

Latest updates

View all

Our pioneering research has been featured in leading medical journals and publications

BiomeBank in the news: